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The discovery of the myofibroblast has opened new
perspectives for the comprehension of the biological
mechanisms involved in wound healing and fibrotic
diseases. In recent years, many advances have been
made in understanding important aspects of myofibro-
blast basic biological characteristics. This review sum-
marizes such advances in several fields, such as the
following: i) force production by the myofibroblast and
mechanisms of connective tissue remodeling; ii) factors
controlling the expression of -smooth muscle actin,
the most used marker of myofibroblastic phenotype
and, more important, involved in force generation by
the myofibroblast; and iii) factors affecting genesis of
the myofibroblast and its differentiation from precur-
sor cells, in particular epigenetic factors, such as DNA
methylation, microRNAs, and histone modification. We
also review the origin and the specific features of the
myofibroblast in diverse fibrotic lesions, such as sys-
temic sclerosis; kidney, liver, and lung fibrosis; and the
stromal reaction to certain epithelial tumors. Finally, we
1340summarize the emerging strategies for influencingmyo-
fibroblast behavior in vitro and in vivo, with the ulti-
mate goal of an effective therapeutic approach for myo-
fibroblast-dependent diseases. (Am J Pathol 2012, 180:
1340–1355; DOI: 10.1016/j.ajpath.2012.02.004)
Myofibroblasts regulate connective tissue remodeling by
combining the extracellular matrix (ECM)–synthesizing
features of fibroblasts with cytoskeletal characteristics of
contractile smooth muscle cells. Since their first descrip-
tion in granulation tissue 40 years ago, remarkable prog-
ress has been made in understanding myofibroblast bi-
ological characteristics and their participation in
physiological and pathological situations.1 It is well es-
tablished that myofibroblasts have multiple origins, con-
tribute importantly to connective tissue remodeling by
exerting traction forces and synthesizing ECM compo-
nents, regress and disappear by apoptosis on wound
epithelialization, and may persist in fibrotic situations and
cause organ dysfunction.1 Since our last review on the
subject in this journal,1 many new findings have emerged
to advance our understanding of myofibroblast biological
features, but many questions remain unanswered. Unre-
solved questions include the following: i) what is the
progenitor or precursor cell for the myofibroblast, ii) is
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myofibroblast contractile activity, and iv) what is the ba-
sis for myofibroblast persistence in chronic or progres-
sive fibrosis? Recent rapid progress in microRNA
(miRNA) and epigenetics research2 has furnished new
tools and concepts for assessing molecular regulation
of myofibroblast differentiation and perpetuation of the
myofibroblast phenotype, as potentially mediated by
epigenetic mechanisms. The ultimate aim is to suggest
therapeutic strategies for influencing the widespread
pathological situations that depend on this enigmatic
cell.
Myofibroblast Basics
During normal tissue repair, such as skin wound healing,
controlled and transient activation of myofibroblasts contrib-
utes to restoration of tissue integrity by forming a mechan-
ically sound scar.1 For example, scars stabilize the heart
muscle after myocardial infarction and tendon, bone, and
cartilage after fracture or rupture.3 However, when myofi-
broblast activities become excessive and persist, beneficial
tissue repair turns into the detrimental tissue deformities
characteristic of organ fibrosis. In this review, we will dis-
cuss in more detail fibrosis of the skin, lungs, liver, and
kidney. In addition to these organs, myofibroblasts play a
substantial role promoting heart fibrosis and vascular re-
modeling, but because of space limitation, these topics are
not covered herein, and we refer the reader to recent re-
views of this rapidly growing body of literature.4,5 Another
fibrotic condition is the desmoplastic or stromal reaction to
epithelial tumors, during which myofibroblasts contribute to
the mediator and mechanical environment that promotes
tumor progression.6 We will discuss the similarities of the
tumor-associated fibroblasts and myofibroblasts with those
present in other fibrotic lesions.
Specific Aspects of Myofibroblast Contraction
High contractile activity of myofibroblasts is necessary for
generating tissue contractures. In addition to the expres-
sion of -smooth muscle actin (-SMA; gene ACTA) in
stress fibers, which promotes stronger force generation
compared with other actin isoforms in fibroblastic cells,
myofibroblasts appear to use specific modes of contrac-
tion.3,7 In contrast to the reversible and comparably
short-lived contraction of striated and smooth muscles,
myofibroblast contractile activity, together with ECM syn-
thesis and degradation, leads to connective tissue re-
modeling, followed by irreversible and long contractures
in a process that can span weeks, months, or even
years.7 It is still unknown how myofibroblasts stabilize
contractions that occur at the cellular or subcellular level
to counteract the stress present in a tissue undergoing
remodeling. Recent in vitro studies8 indicate that myofi-
broblasts use a lockstep or ratchet mechanism of cyclic
and incremental contractile events. This mechanism con-
sists of strong (micronewtons) and far-ranging (tens of
micrometers) contractions mediated by RhoA/Rho-asso-
ciated kinase and weak (approximately 100 pN) andshort-ranging (approximately 0.4 m) cyclic contractions
promoted by changes in intracellular calcium concentra-
tions.8 The model proposes that strong isometric contrac-
tion generates slack in the myofibroblast-associated fi-
brous and stressed collagen. Such tension-released
fibrils are then straightened by the weak, but repeated,
subcellular contractile events. By local ECM remodeling
and/or deposition of new ECM, the shortened and re-
peatedly stressed collagen fibrils stabilize the status
quo of the ECM, and a new myofibroblast contraction
cycle can begin. It is intriguing that the level of stress
(ie, the resistance of collagen fibers to pulling) may
determine which mechanism of contraction will be en-
gaged.
Characteristic Features of the Myofibroblast
Although there is considerable evidence to indicate the
fibroblastic origin of myofibroblasts, other cell types,
mostly from mesenchymal lineages, have been sug-
gested as alternative or additional precursors.1 Because
different subsets of myofibroblast precursors are re-
cruited in different organs, we will further address the
question of the myofibroblast origin later. To target the
fibrotic activity of myofibroblasts, irrespective of their
provenance, it is important to define common denomina-
tors, a need that has stimulated the search for specific
molecular markers. The most widely used molecular
marker of the differentiated myofibroblast in research and
clinical diagnostics is the de novo expression of - SMA.1
The convenience of a unique molecular marker has fos-
tered the misconception that a myofibroblast must ex-
press -SMA to be a myofibroblast. However, the most
important defining feature of myofibroblasts is the
de novo development of in vivo stress fibers and contrac-
tile force.3,7 Several novel markers and modulators of the
myofibroblast phenotype have been suggested. These
include endosialin in tumor-associated fibroblasts,9 P311
in hypertrophic scar myofibroblasts,10 integrin 111 in
fibroblasts from various sources,11 osteopontin in cardiac
or dermal fibroblasts,12 and periostin13,14 (Table 115–77).
It remains to be confirmed whether these markers are
tissue and/or condition specific or whether they are useful
in identifying myofibroblasts in more general terms. To
our knowledge, none of the other markers described over
the years is unique to the myofibroblast.
Myofibroblast-Inducing Factors and Conditions
Mechanical resistance of the ECM, in conjunction with the
action of profibrotic transforming growth factor 1
(TGF1), is an amply documented primary stimulus for
myofibroblast differentiation and persistence.1 Myofibro-
blasts develop in vitro and in vivo their highly contractile
cytoskeletal apparatus only above a certain ECM stiff-
ness threshold.3,62 Various fibrotic organs and tissues
have recently exceeded this threshold at the microme-
chanical level.78–80 Tissue stiffness increases as a con-
sequence of ECM-remodeling activities of fibroblasts and
myofibroblasts.63 Contracting cells then generate the
conditions that make them even more contractile in a
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question of how fibroblastic cells are initiated to become
contractile in the soft ECM present after the injury may be
answered by recent biomechanical studies. In an animal
model of liver fibrosis, increased tissue stiffness pre-
Table 1. Myofibroblast-Modulating Factors
Myofibroblast-inducing
factors
Myofibroblast-
suppressing factors
Transcription-Regulating Factors
Smad3 and Smad215 Smad7
MeCP216 NF-B30
KLF517 KLF415,22,31
HMGA218 PPAR30,32
SRF19,20 Nkx2.533
RTEF-121 YB-134
Sp1 and Sp317,22
C/EBP23
CSL24
c-Myb25
MRTF-A/MRTF-B20,26–28
Fli-129
Epigenetic Regulators and miRNAs
DNMT135 Other DNMTs16,42
HDAC436,37 miR-2943–48
(HDAC6 and HDAC8)36
miR-19238 Let718
miR-13230 miR-200a49
miR-2139
miR-12940
miR-200b/c38
miR-216a41
Growth Factors, Cytokines, and Others
TGF150–52 Interferon-60
P31110 CXCL1061
Wnt51,53
Jagged151,54
FAK52,55
NOX456–59
ECM, ECM-Modulating Proteins, and Physical Factors
Stiff ECM3,62–65 Soft ECM3,62,63
ROS66,67
LOX68
LOXL269,70
Lysyl hydroxylase and PLOD271
Osteopontin72
Periostin13,14
CCN2 (CTGF)51,73,74
ED-A fibronectin1,75,76
Membrane-Bound and Surface-Expressed Proteins
Endosialin (Tem1)9
Integrin
11111
3111,53
v311,50
v550
Notch124,51,54,77
The table summarizes recently identified proteins and factors that have
regulated myofibroblast differentiation either directly or indirectly. For
well-established myofibroblast modulators, such as TGF1, review arti-
cles are referenced.
C/EBP, CCAAT enhancer binding protein; CTGF, connective tissue
growth factor; ED-A, extradomain A; FAK, focal adhesion kinase; Fli-1,
friend leukemia integration; KLF, Kruppellike factor; PLOD, procollagen-
lysine, 2-oxoglutarate 5-dioxygenase; ROS, reactive oxygen species;
RTEF, R-transcription enhancer factor; Sp, specificity protein; SRF, serum
response factor; YB-1, Y-box binding protein-1.cedes the activation of fibroblastic cells and the accumu-lation of collagen, thus suggesting that such early me-
chanical changes may be sufficient to trigger the con-
traction cascade.68 Collagen cross-linking catalyzed by
lysyl oxidase (LOX) enzymes is one possible factor re-
sponsible for early structural changes and tissue stiffen-
ing in these conditions.68 Fibrosis-specific and stable
collagen cross-links are further formed by lysyl hydroxy-
lase and pro-collagen-lysine, 2-oxoglutarate 5-dioxyge-
nase, which are responsible for pyridinoline and alde-
hyde-derived collagen cross-links in the fibrotic skin.71
Furthermore, antibody-mediated inhibition of the enzyme
LOX-like 2 (LOXL2) suppresses fibrosis and its progres-
sion in a variety of organ systems, including tumor des-
moplasia.69 However, it remains unclear whether this ef-
fect is due to reduced ECM stiffness. The potential role of
initial tissue stiffening in the onset of fibrosis is particularly
interesting given that cultured myofibroblasts can acti-
vate latent TGF1 from a sufficiently stiffened ECM by
integrin-mediated contraction.64,65 A purely mechanically
driven mechanism of profibrotic growth factor activation
has been experimentally proved in a cell-free system81
and is supported by the recently revealed structure of
latent TGF1.82 These findings establish a direct link
between the mechanical and chemical factors regulating
myofibroblast differentiation and ultimately causing fibro-
sis.50,83 Table 1 summarizes myofibroblast-inducing and
myofibroblast-inhibiting factors.
Myofibroblast Differentiation and Regulation of
ACTA Gene Expression
Because -SMA expression is a common key element for
detection of myofibroblast differentiation and a major player
in contractile force production, most of the available data
focus on the regulatory mechanisms underlying expression
of this gene. Abundant information is available on transcrip-
tional regulation of the ACTA gene, which indicates complex
combinatorial mechanisms involving both stimulatory and
inhibitory factors (Figure 1A and Table 1).
Activators of the -SMA Promoter
Among the activators are serum response factor and the
transcription enhancer factor-1 family member R-transcrip-
tion enhancer factor, which bind to CC(A/T)6GG (CArG)
and CATTCCT (MCAT) elements, respectively, in the up-
stream regulatory sequence of the -SMA promoter.19,21 In
addition to the importance of Smad3 and its binding ele-
ment,15 another element found to be important in TGF1-
induced differentiation is a proximal TGF control element,
to which several factors [eg, Krüppel-like factor 5, specific-
ity protein (Sp) 1, and Sp3] can bind to activate transcrip-
tion.17,21,22 Other upstream elements include the TGF hy-
persensitivity region and an Smad-binding element, which
are activated by binding to Sp1/Sp3 and Smad3, respec-
tively.15,22 Studies in several different cell types have impli-
cated additional transcription factors, such as CCAAT en-
hancer–binding protein , CSL (from CBF1/RBP-J in
mammals, Suppressor of Hairless [Su(H)] in Drosophila and
Xenopus, and Lag-1 in Caenorhabditis elegans) (a down-
Myofibroblast Biology 1343
AJP April 2012, Vol. 180, No. 43stream target of Notch signaling), and c-Myb, in regulation
of ACTA gene expression (Table 1).23–25
An important factor linking ACTA gene transcription to
the level of mechanical stress and the state of the con-
tractile cytoskeleton is myocardin-related transcription
factor A (MRTF-A).20,26,27 In a mechanism that involves
the F-actin–organizing factor mDia1, MRTF-A docks to
CArG elements and enhances the transcriptional activity
of serum response factor.20 MRTF-A and MRTF-B also
mediate TGF1-induced myofibroblast differentiation
and transcription of smooth muscle genes in fibro-
blasts.28 Other mechanically regulated transcription of
fibrosis-related genes have been recently reviewed.20
Repressors of the -SMA Promoter
Several factors have down-regulated -SMA expression
and, thus, may be responsible for active suppression of
myofibroblast differentiation (Table 1). Among these fac-
tors is Kruppellike factor 4, which can compete for bind-
ing to the TGF control element by its activators and
interact with the Mad homology 2 (MH2) domain of
Smad3 to suppress its binding to the ACTA promoter.31
Additional repressors are Nkx2.5, peroxisome prolifera-
tor–activated receptor (PPAR)-, and Y-box binding pro-
tein-1.32–34 In the case of Nkx2.5, reduction in its expres-
sion correlates with myofibroblast differentiation in lung
fibroblasts. Thus, differentiation may be mediated by a
derepression mechanism dependent on decreased ex-
pression of one or more of these repressors.
Smad-Independent Regulation of the -SMA
Promoter
In addition to Smad signaling, the multiple, complex sig-
naling mechanisms implicated in regulation of myofibro-
blast differentiation may also involve mitogen-activated
protein (MAP) kinases.15 Depending, in part, on the pre-
cursor cell type, Wnt signaling pathways may also be
involved.53 Notch signaling is important in endothelial-to-
mesenchymal transition and myofibroblast differentiation
from lung fibroblasts.24,54 This is likely mediated by CSL
interacting with its binding element identified in the ACTA
promoter. Induction of Jagged1, a ligand for Notch1,
results in activation of this signaling pathway, with subse-
quent activation of ACTA gene transcription. Impaired
Notch signaling in vivo results in reduced myofibroblast dif-
ferentiation in an animal model.54 Another important path-
way in myofibroblast differentiation associated with the des-
moplastic response in tumors is Hedgehog signaling,
although the downstream target gene(s) have not been
identified.84 All these differing signaling pathways are likely
to work in concert at one level or another in more complex
scenarios to ultimately affect ACTA gene expression, both
directly and indirectly, via other regulatory genes.
Myofibroblast Epigenetics: A Fibrotic Memory?
Various approaches have demonstrated differences in
the protein, gene, and transcriptional profiles betweenmyofibroblast precursors from different origins and their
fibrotic counterparts.85,86 Microarray studies have shown
up-regulation of many genes, consistent with activation
by TGF1, Wnt, and connective tissue growth factor
(CCN2) signaling pathways, which are abnormally ex-
pressed in patients with fibrotic disorders.85,87 These fi-
brotic signatures tend to disappear in explanted fibro-
blasts compared with whole tissue from the same
patients.88 A common observation in profiling studies is
that specific signatures of myofibroblasts are retained
over several passages in vitro, suggesting a myofibro-
blast memory that may be mediated by epigenetic mod-
ifications, with consequent preservation of the myofibro-
blast phenotype and its persistence. Epigenetic
regulation of gene expression in a variety of fibrotic con-
ditions has involved DNA methylation, modification of
histones, and regulation of miRNAs targeting select
genes (Figure 1, B and C).
Myofibroblast DNA Methylation
In the case of DNA methylation, modification at CpG
islands represents an important mechanism for gene
silencing, and this appears to be the case for the ACTA
gene16,89 (Figure 1B). Lung alveolar epithelial type II
cells, which do not express -SMA, exhibit high levels
of methylation in the three CpG islands identified in the
regulatory regions of this gene and in intronic regions.
In contrast, lung fibroblasts exhibit significantly lower
levels of DNA methylation in this gene, and its inhibition
using 5-aza-2=-deoxycytidine activates gene transcrip-
tion. DNA methylation is not limited to the ACTA gene in
fibrotic conditions. In lung fibroblasts, hypermethyl-
ation of the promoter region of the TYHY1 gene has
been implicated in its silencing, correlating with fibro-
sis in the lung.89,90 In scleroderma fibroblasts, ECM-
inhibitory genes, such as Smad7 or Fli-1 are also hy-
permethylated and consequently down-regulated,
suggesting that DNA methylation could cause dere-
pression of ECM genes involved in fibrosis.29
Similarly induced specific deficiency of DNA methyl
transferases (DNMTs), using small-interfering RNAs,
causes activation of ACTA gene transcription in these fibro-
blasts42 (Figure 1B). In the fibrotic kidney, DNMT1 is asso-
ciated with persistent fibroblast activation and fibrogenesis
via promotion of hypermethylation of RASAL1, a gene that
encodes an inhibitor of the Ras oncogene.35 DNMT1/
heterozygous mice exhibit reduced renal fibrogenesis and
kidney fibrosis. Conversely, induced DNMT overexpression
in lung fibroblasts, using expression plasmids, results in
repression of ACTA gene expression and, thus, of myofibro-
blast differentiation.35 The use of these approaches to alter
DNMT expression and/or inhibition of DNA methylation is
likely to affect other genes as well, which may indirectly
affect ACTA gene expression. This is the case in a
study30 of hepatic stellate cells (HSCs), in which inhi-
bition of DNA methylation results in activation of PPAR
and NF-B, which then repress ACTA gene expression.
Direct and indirect effects of the methylated DNA-bind-
ing protein MeCP2 have also been observed. MeCP2
binds directly to the ACTA gene promoter and is es-
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AJP April 2012, Vol. 180, No. 4Figure 1. Myofibroblast epigenetics. A: Transcriptional regulation of the ACTA gene in myofibroblast differentiation. Activating or repressing transcription factors
are shown directed at the relative locations of their cognate binding elements in the ACTA gene promoter. The interaction of Kruppellike factor (KLF) 4 with Smad3
results in decreased Smad3 binding to the Smad-binding element (SBE). In contrast, MRTF enhances serum response factor binding to its cognate element to
activate differentiation. PPAR and NF-B are also shown, but the location/nature of their direct interaction with the promoter is uncertain (indicated with a
question mark). The activation of Notch signaling activates its downstream factor CSL. CArG, CC(A/T)6GG; C/EBP, CCAAT enhancer binding protein; CSL, from
CBF1/RBP-J in mammals, suppressor of hairless [Su(H)] in drosophila and xenopus, and Lag-1 in Caenorhabditis elegans; IM-CAT, binding element with sequence
CATCCT; LAP, liver activator protein; LIP, liver inhibitory protein; NKE, Nkx2.5 binding element; SRF, serum response factor; TEF, transcription enhancer factor;
THR, TGF-1 hypersensitivity region; TSS, transcription start site. B: DNA methylation and miRNAs in myofibroblast differentiation. Methylated CpG islands are
shown in the ACTA gene promoter in the fibroblast, which are maintained by DNMT. The differentiated myofibroblast shows reduced methylation with activation
of ACTA gene expression. The methylated DNA-binding protein MeCP2 promotes myofibroblast differentiation; however, multiple target genes are regulated by
this protein. The indicated miRNA species regulate their target mRNAs with downstream consequences on myofibroblast differentiation, as indicated. Although
ACTA is used as a hallmark gene of the myofibroblast, other fibrosis-relevant genes have been regulated by hypermethylation as well (see Myofibroblast DNA
Methylation). C: Histone deacetylation and myofibroblast differentiation. The indicated HDAC isoforms modulate differentiation via multiple mechanisms. In
addition, inhibition/depletion of HDAC4 suppresses TGF activation of Akt via 5=-TG-3=-interacting factor 1,2 (TGIF1,2) and protein phosphatase 2A/1
(PP2A/PP1).
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deficiency significantly reduces pulmonary fibrosis
and myofibroblast differentiation in an animal model.
The relative contribution of these direct versus indirect
mechanisms may be decisive in determining the ulti-
mate effect on myofibroblast differentiation.
Myofibroblasts, Fibrosis, and miRNAs
In addition to epigenetic modulation through DNA methyl-
ation, different miRNAs appear to contribute to the myofi-
broblast memory43 (Figure 1B and Table 1). miR-29 expres-
sion is markedly reduced in skin biopsy specimens and
explanted skin fibroblasts from patients with scleroderma,
suggesting a post-translational epigenetic mechanism for
increased ECM gene expression.44 In fibrotic lung, low lev-
els of miR-29 correlate with high expression levels of profi-
brotic genes, including previously unrecognized ECM and
ECM remodeling genes. Knockdown or TGF1-mediated
down-regulation of miR-29 in cultured lung fibroblast dere-
pressed fibrosis-associated genes.45 Down-regulation of
miR-29 in cardiac fibroblasts in vitro and in vivo induces
fibrosis-associated genes, whereas its overexpression has
a fibrosis-suppressing effect.46 A comparable fibrosis-sup-
pressing role has been demonstrated for miR-200a in the
kidney49 and liver.47
Conversely, in an animal model of kidney fibrosis, up-
regulation of miR-192 is reported on TGF1 signaling,
and overexpression of an miR-192 analogue induces
ECM production.38 Similarly, miR-129,40 miR-192, miR-
200b/c,38 and miR-216a41 promote expression of fibrotic
genes inmousemesangial cells. AnothermiRNA involved in
fibrosis is miR-132, which mediates inhibition of MeCP2
expression, reduces PPAR expression, and consequently
enhances ACTA gene expression in lung fibroblast.30 Such
an indirect mechanism has also been reported for addi-
tional miRNA species. Among these, Let7 andmiR-21 affect
lung myofibroblast differentiation via effects on HMGA2 and
Smad7, respectively, although additional effects on other
target genes have not been excluded.18,39 Future miRNA
profiling studies, such as the one recently started for bleo-
mycin-induced lung fibrosis,91 will hopefully provide a more
complete picture of the miRNA species involved in the dif-
ferent aspects of fibrosis.
Myofibroblast Histone Modifications
Histone modification is involved in the perpetuation of
fibrosis. The importance of histone modification in regu-
lation of ACTA gene expression is generally indirect.30
The histone deacetylases (HDACs) 4, 6, and 8 have been
identified as the key HDACs involved in this mechanism36
(Figure 1C and Table 1). Although HDAC4 possibly af-
fects the activation of Akt in TGF1-induced differentia-
tion,37 the direct target genes of these modified histones
have not been identified. Histone acetylation is usually
associated with activation of target gene expression;
thus, the mechanism of this inhibition on ACTA gene
expression is likely due to activation of other genes that
repress its expression. In addition to histone acetylation,methylation of histones is involved in myofibroblast de-
velopment and fibrosis.30 Considering the rapid progress
made in understanding epigenetic processes, it will be
years until the first potential targets are identified and
tested for their anti-fibrotic potential.
Organ Fibrosis
Systemic Sclerosis
The Role of Fibrosis in Systemic Sclerosis
Systemic sclerosis or scleroderma is a chronic auto-
immune and fibrotic disease of unknown etiology with no
effective disease-modifying therapies and significant
mortality. The disease is highly heterogeneous in its clin-
ical manifestations. Widespread fibrosis affecting virtually
every organ distinguishes scleroderma from organ-
based fibrotic processes, such as pulmonary fibrosis,
keloids, glomerulosclerosis, and hepatic fibrosis. The
dermis, lung parenchyma, heart, gastrointestinal tract,
tendons, and ligaments are prominently affected, with
endocrine organs, such as the thyroid gland, occasion-
ally affected.51 Interestingly, neither the liver nor the cen-
tral nervous system show significant fibrosis in sclero-
derma. Activated fibroblasts and myofibroblasts are the
primary effector cells of fibrosis in scleroderma.51
The skin in scleroderma is characterized by replacement
of the normal dermal architecture with collagen-rich con-
nective tissue. Progressive dermal thickening and sclerosis
obliterate eccrine and sebaceous glands, hair follicles, and
small blood vessels. Analysis demonstrates excessive de-
position of the main fibrillar collagens (types I and III) and
types V and VII collagens, normally restricted to the dermal-
epidermal junction.92 The extradomain A fibronectin splice
variant, which is critical for myofibroblast differentiation,
shows increased deposition.93 Other structural ECM mole-
cules that are aberrantly expressed in scleroderma include
fibronectin, proteoglycans, fibrillin, and elastin fibrils.94
Fibrillin accumulation is of particular interest, because fibril-
lin-1 regulates the activation of ECM-bound latent TGF1,
and mice with a fibrillin-1 mutation (tight skin mice) develop
a sclerodermalike phenotype.95 Microarray analysis of
scleroderma skin reveals up-regulation of genes normally
associated with bone and cartilage, including type XI col-
lagen and cartilage oligomeric matrix protein (COMP). In-
tegrins involved in cell-cell and cell-ECM adhesion and la-
tent growth factor activation are also overexpressed in the
lesional tissue.86,87
The Origin of Myofibroblasts in Scleroderma
Fibroblasts and myofibroblasts are the principal stro-
mal cells responsible for the excessive ECM deposition
and remodeling in scleroderma. Although in situ hybrid-
ization studies have identified an increased proportion of
biosynthetically active fibroblasts in scleroderma dermis,
in vitro clonal analysis of explanted skin fibroblasts shows
substantial heterogeneity with respect to collagen syn-
thesis, suggesting the existence of distinct subpopula-
tions of dermal mesenchymal cells with different origins.
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lesional scleroderma but are not detected in healthy
skin.93,96 Accumulation is prominent in areas with signif-
icant collagen deposition. Myofibroblastic cells are also
observed in the esophagus and lung, even in the liver,
despite the absence of fibrosis. Culture of bronchoalveo-
lar lavage fluids from patients with scleroderma shows
spontaneous outgrowth of -SMA–positive cells with high
production of collagen and fibronectin.51 In contrast,
myofibroblasts are not detected in bronchoalveolar la-
vage fluids from healthy individuals. The number of myo-
fibroblasts in the lesional skin in scleroderma correlates
with both the extent of local collagen deposition and the
clinical assessment of skin stiffness.97 Moreover, the
myofibroblast score in the skin shows a decrease over 6
to 12 months in patients treated with cyclophosphamide,
suggesting that myofibroblast levels in the skin may be
used as biomarkers of changing skin involvement.
The origin of myofibroblasts in the fibrotic lesions has
not been conclusively established. They may arise from
the in situ activation of normally quiescent resident fibro-
blasts in response to extracellular triggers, such as
TGF1, Wnt, Jagged/Notch, CCN2, endothelin-1, lyso-
phophatidic acid, and other signaling molecules, as well
as hypoxia and mechanical stress due to increased ECM
stiffness.51 Each of these stimuli, which induce -SMA
expression and stress fiber formation in explanted
healthy skin fibroblasts, has been aberrantly expressed
or regulated in scleroderma. Alternatively, myofibroblasts
in scleroderma lesional tissue may arise from other cell
types, including vascular smooth muscle cells, peri-
cytes,93 and endothelial cells under the influence of
TGF198 or epithelial cells in the skin or lungs.99,100 Be-
cause both myofibroblasts and pericytes are associated
with vascular remodeling and injury, which are prominent
in patients with scleroderma, vascular smooth muscle
cells and pericytes might provide the pathogenetic link
between vascular injury and fibrosis characteristic of
scleroderma. Although the significance of mesenchymal
differentiation pathways in the context of scleroderma
has not been conclusively demonstrated, and the mech-
anisms underlying such cellular plasticity in vivo remain
mostly unknown, it is tempting to consider scleroderma
therapies that are based on targeting these events.
Persistence of Scleroderma Fibroblasts
Historically, the study of scleroderma fibroblasts fo-
cuses primarily on the skin, because it is readily acces-
sible for biopsy. Pioneering studies by Leroy101 30 years
ago are the first to demonstrate the feasibility of studying
explanted skin fibroblasts in scleroderma. These obser-
vations indicate that scleroderma-derived skin fibroblasts
display a biosynthetically activated phenotype in vitro that
is independent of extracellular signals. A cell-autono-
mous activated phenotype is maintained for multiple in
vitro passages.101 These studies have been subse-
quently reproduced and extended by other investiga-
tors.102 In some studies, most explanted scleroderma
fibroblasts are positive for -SMA in vitro, with increased
production of collagen and tissue inhibitor of metallopro-teinase.103 Moreover, myofibroblasts explanted from
scleroderma skin are resistant to Fas-induced apopto-
sis.96 Apoptosis resistance may be due to activation of
the Akt prosurvival pathway and may account for the
persistence of myofibroblasts in scleroderma skin.104 An-
other potential mechanistic explanation accounting for
the persistent -SMA expression in scleroderma is pro-
vided by the demonstration that pharmacological inhibi-
tion of focal adhesion kinase phosphorylation signifi-
cantly attenuates the myofibroblast phenotype of these
cells.55 Scleroderma fibroblasts show an elevated level of
focal adhesion kinase phosphorylation, presumably re-
flecting their stimulation by autocrine TGF1. Consistent
with the autocrine TGF1 hypothesis, explanted sclero-
derma fibroblasts show constitutive nuclear localization of
phosphorylated Smad2/3, even in the absence of added
TGF1.105 These studies suggest that an autocrine TGF1-
stimulatory loop induces focal adhesion kinase phosphory-
lation and apoptosis resistance, with consequent persis-
tence of -SMA–expressing myofibroblasts.52
In addition to enhanced ECM production, scleroderma
fibroblasts in culture produce chemokines and growth
factors and spontaneously generate reactive oxygen rad-
icals, such as H2O2, through the NADPH oxidase (NOX)
complex pathway, which is up-regulated in scleroderma
skin.66 In turn, intracellular production of reactive oxygen
species is at least partially responsible for the constitutive
up-regulation of collagen synthesis in these cells. The
expression of surface receptors for relevant growth fac-
tors and chemokines, including TGF1, platelet-derived
growth factor, and CCR2, are also elevated on sclero-
derma fibroblasts, suggesting an additional feed-forward
amplification mechanism that might underlie the persis-
tently activated phenotype.106
Renal Fibrosis
Renal interstitial fibrosis is a common pathological feature
of chronic kidney disease (CKD), irrespective of etiology.
The myofibroblast is a major player in the onset and
evolution of renal fibrosis and has been implicated in
pathogenesis.107
The Origin of Renal Myofibroblasts
Despite their pivotal role in disease progression, the
source of renal myofibroblasts is still a matter of debate.
Several progenitors have been proposed in addition to local
fibroblasts, including circulating fibrocytes, local peri-
cytes,108,109 and resident epithelial cells, through
epithelial-to-mesenchymal transition (EMT).110 The possible
contribution of EMT to fibrosis in vivo was recently chal-
lenged by a study108 using a mouse model of renal inter-
stitial fibrosis and genetic cell lineage tracing. However,
under the same conditions of kidney obstruction, but using
a different approach, EMT was observed by another
group.111 These conflicting data have been addressed
elsewhere in several excellent critical articles.112,113
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Contributes to Kidney Myofibroblast Generation
It appears increasingly likely that loss of the normal,
homeostatic microenvironment, due to alterations in the
tubulointerstitium per se, triggers myofibroblast activation
and causes progression of fibrosis.114 This established
concept is based on the histological evidence that prox-
imal tubule cell (PTC) injury precedes interstitial fibrosis
and that regions of active interstitial fibrosis predomi-
nantly exhibit a peritubular, rather than a perivascular,
distribution. This notion is supported by in vitro studies115
showing that cortical fibroblast proliferation is stimulated
by paracrine signals generated by PTC in co-culture.
Moreover, in proteinuric nephropathies with progres-
sive injury of the glomerular filtering barrier, abnormal
uptake of ultrafiltered proteins by PTCs induces release
of TGF1, which, in turn, promotes interstitial fibrogen-
esis.116 Re-establishment in vitro of epithelial cell polar-
ization and differentiation inhibits proliferation of mesen-
chymal stem cells (MSCs) from co-cultured adipose
tissue fragments,117 confirming that uninjured differenti-
ated renal tubular cells in their normal configuration con-
tribute to the maintenance of the homeostatic state of
MSCs. A seminal work73 evaluating the effects in vitro of
aristolochic acid on several PTC lines reveals that dam-
aged epithelial cells markedly up-regulate expression of
profibrotic TGF1 and CCN2. This up-regulation is associ-
ated with amarked increase in the percentage of cells in the
G2/M phase of the cell cycle, which is confirmed in vivo
using different acute kidney disease mouse models.73 The
contribution of PTCs is further supported in a tetracycline-
inducible transgenic mouse model, in which conditional
overexpression of TGF1, limited to renal tubules, induces
widespread peritubular fibrosis and focal nephron degen-
eration.114 During the course of this process, the remnants
of one cell were removed by phagocytosis by neighboring
cells with a mechanism akin to that seen in tubular atro-
phy.118 Outside these degenerating tubules, a marked pro-
liferation of resident fibroblasts, without contribution of EMT
and only sparse macrophages, is associated with progres-
sive deposition of ECM.
Notch signaling is involved in orchestrating kidney de-
velopment in tubular epithelial cells and plays a role in
tubulointerstitial development.77 Interestingly, specific
expression of cleaved Notch1 in tubular epithelial cells
causes fibrosis in the surrounding interstitium, with a his-
tological appearance that resembles the lesions seen in
human CKD. Conversely, tubular-specific deletion of
Notch signaling protects against kidney fibrosis.77 The
importance of an altered tubule-interstitial microenviron-
ment to fibrosis is also supported by the clinical obser-
vation that the severity of acute kidney injury (AKI) with
massive tubular epithelial cell death is a robust predictor
of progression to CKD.119 Even if mechanisms for AKI to
CKD progression are unknown, it can be hypothesized
that AKI progression toward CKD arises from incomplete
repair of regenerating tubules. Another explanation is that
persistently high profibrotic signaling activity in regener-
ating tubule epithelium produces paracrine activity that
drives fibroblast proliferation and inflammation. Thus, insevere AKI and CKD, epithelial-mesenchymal cross talk
alterations possibly lead to tubulointerstitial fibrosis and
kidney failure.
It appears that an altered renal microenvironment is
the main cause of myofibroblast differentiation in renal
fibrosis, and cross talk between epithelial cells and
fibroblasts is pivotal for maintenance of the local ho-
meostatic microenvironment, a concept previously
suggested for idiopathic pulmonary fibrosis120,121 and
for stromal reaction to carcinoma.122 Therefore, inter-
fering with tubular-mesenchymal cross talk emerges as
a promising strategy for the development of new anti-
fibrotic drugs, which are not solely directed to block
myofibroblast activation.
Pulmonary Fibrosis
Structural Aspects of the Lung Relevant for Fibrosis
The adult human lung is a structurally complex organ
system composed of40 cell types. The upper conduct-
ing airway, composed of the trachea and a series of
branching bronchi and bronchioles, terminates in the
gas-exchanging alveoli of the lower respiratory tract. At
each level, the epithelium-lined airways and endothelium-
lined vasculature are integrated, both structurally and
functionally, by an interconnected reticulum of mesen-
chymal cells and ECM extending from the upper airway
down to the alveoli.123 The lung is susceptible to various
forms of short-/long-term injuries, both airborne and
blood borne, that may culminate in fibrosis. In addition,
fibrosis may involve the small conducting airways (eg,
asthma and chronic obstructive pulmonary disease), vas-
culature (eg, pulmonary hypertension), or pleura (eg,
pleural fibrosis). Some forms of fibrosis, such as acute
lung injury or cryptogenic organizing pneumonia, are at
least partially reversible, whereas others, in particular
idiopathic pulmonary fibrosis, are progressive and usu-
ally fatal.120,121 A central role for the myofibroblast in
tissue remodeling and fibrosis involving these different
tissue compartments and varied disease processes has
been demonstrated.124
Origin of Lung Myofibroblasts
The concept that lung myofibroblasts may derive from
multiple cellular sources, including bone marrow progen-
itors and the lung epithelium, has been previously re-
viewed.1 Depending on the experimental model and tools
used, conclusions on participation of myofibroblast pro-
genitors to lung fibrosis sometimes appear contradictory.
For example, recent studies using a surfactant protein
C-CreER(T2) knock-in allele to follow the fate of type II
alveolar cells in vivo indicated no contribution to myofi-
broblasts in the fibrotic reaction to an acute lung injury
involving intratracheal instillation of bleomycin.125 The
resolving nature of bleomycin-induced lung fibrosis in
mice contrasts with the progressive nature of the most
recalcitrant forms of lung fibrosis in humans, in particular
idiopathic pulmonary fibrosis. Whether chronicity of the
injury may account for processes, such as EMT, remains
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brotic process may also be linked to the epigenetic (dys)
regulation2,16,42,89 that controls the differentiation and
fate of endogenous reparative cells.
Specific Features of Myofibroblasts in the Lung
The fate of myofibroblasts, regardless of their origin(s),
in injured tissues may ultimately determine whether nor-
mal healing occurs or whether progression to end-stage
fibrosis ensues.121,126 There is likely to be significant
heterogeneity in lung fibroblasts, including anti-fibrotic
subpopulations, such as Thy-1–expressing fibroblasts
and lipofibroblasts.65,89,90 The mechanisms that produce
an apoptosis-resistant myofibroblast phenotype have not
been fully elucidated, although some of the same factors
that mediate myofibroblast differentiation appear to pro-
mote myofibroblast survival.90,127,128 A member of the
NOX family of enzymes, NOX4 has been required for
TGF1-induced myofibroblast differentiation, ECM pro-
duction, and contractility of lung myofibroblasts.56,57
NOX4 is up-regulated in lungs of human subjects with
idiopathic pulmonary fibrosis, and genetic or pharmaco-
logical targeting of NOX4 attenuated lung fibrogenesis in
two different murine models of lung injury.56 It is unknown
if the profibrotic effects of NOX4 are related solely to
activation of myofibroblasts or if its expression in alveolar
epithelial cells may also contribute to fibrogenesis.58,59 It
is also yet to be determined if targeting NOX4 modulates
the apoptosis-resistant phenotype of myofibroblasts and
whether this strategy may be effective in established
fibrosis. However, the proof of concept for therapeutic
targeting of prosurvival signaling with a protein kinase
inhibitor in animal models of pulmonary fibrosis has been
demonstrated.129
Another potential therapeutic strategy is to induce
dedifferentiation of myofibroblasts as a mechanism for
myofibroblast deactivation in progressive fibrotic disor-
ders.130 Cellular plasticity, specifically the ability of dif-
ferentiated cells to dedifferentiate into more primitive mul-
tipotent or pluripotent progenitor cells, appears to be
important in the remarkable regenerative potential ob-
served in amphibians. The extent to which such mecha-
nisms (or the lack thereof) explain the more limited re-
generative capacity in mammals is unknown. It has also
been proposed that lung fibrosis may represent a
process of disordered redevelopment, in which there
exists an aberrant recapitulation of developmental path-
ways.131 Further studies on myofibroblast plasticity and
its capacity for dedifferentiation may provide additional
insights into tissue repair and fibrosis.
Liver Fibrosis
Characteristics of Liver Fibrosis
In experimental and clinical liver fibrosis, -SMA–ex-
pressing myofibroblasts are the major source of fibrillar
collagen and other ECM proteins. Although the impact of
excessive and abnormal ECM deposition is well evalu-
ated in the liver, little is known about the role of myofibro-blast contraction. The contractive nature of liver fibrosis is
suggested by the smaller size of the fibrotic liver (relative
to the healthy liver) and its irregular or nodular surface
due to underlying scar tissue. Collapse of the liver paren-
chyma results in a reduction of the distance between
portal zones, which, together with ECM synthesis, is part
of the fibrotic process. Distortion of liver architecture
characterizing advanced fibrosis and shunting of the por-
tal blood along porto-portal and porto-central fibrotic
septa, away from hepatocytes, results in hepatic failure
and portal hypertension. It is conceivable that these
changes are mainly due to tissue remodeling and de-
pend on contractile forces exerted by myofibroblasts in
addition to ECM deposition.
Origins of Liver Myofibroblasts
Myofibroblasts are absent from normal liver. They
are derived primarily from activated hepatic perisi-
nusoidal cells (HSCs), at least in experimental liver
injury.132 However, other potential precursor cells are
embedded in the portal tract stroma around portal
structures, including vessels and biliary structures. For
example, portal fibroblasts (PFs) are able to acquire a
myofibroblastic phenotype,133 and their contribution
may be more important than generally assumed.134
The contribution of liver MSCs to the myofibroblast
population is as yet unclear. These mesenchymal pro-
genitor cells are usually identified by the combined
expression of different specific surface marker proteins
and their capacity to differentiate into different mesen-
chymal cell lineages. The potential of MSCs to differ-
entiate into myofibroblasts has gained increasing at-
tention; however, it is unclear whether this fate is
beneficial or detrimental for normal tissue repair and
the envisaged medical use of MSCs for tissue regen-
eration purposes.135 The association of MSCs with the
well-known epithelial stem cells located in Hering’s
canals may constitute a niche, a concept that is being
explored in the liver.136 Several studies have demon-
strated that, after injury, many myofibroblasts may orig-
inate from bone marrow,137 but the contribution of
these cells to collagen production is not known.138
Lineage-tracing studies fail to demonstrate the gener-
ation of myofibroblasts from hepatic epithelial cells
(hepatocytes and cholangiocytes) by EMT.139 How-
ever, the controversy about the ability of hepatic
epithelial cells to become myofibroblasts remains un-
settled.113 Thus, the possibility that MSCs, bone mar-
row–derived cells, and EMT may represent alternative
sources of myofibroblasts cannot be excluded.
Evidence for the Reversibility of Myofibroblast
Differentiation in Specific Liver Subpopulations
It is increasingly accepted that, depending on the un-
derlying causative factor (eg, alcohol abuse, viral hepa-
titis, or biliary cholestasis), liver fibrosis may involve dif-
ferent fibrogenic cell subpopulations. To our knowledge,
no reliable markers have been identified that allow unam-
biguous discrimination between HSC- and PF-derived
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ported between these two fibrogenic cell populations,
concerning the mechanisms underlying myofibroblastic
differentiation, activation, and deactivation.140 After iso-
lation from healthy rat liver and culturing under the same
conditions, both HSCs and PFs acquire a myofibroblast
phenotype. HSC-derived myofibroblasts display rounded
and spread morphological characteristics with an en-
larged cytoplasm and, more important, a poor survival
after two to three passages. Conversely, PF-derived myo-
fibroblasts have more elongated morphological charac-
teristics and proliferate over multiple passages. In vivo,
during liver repair, HSC- and PF-derived myofibroblasts
display different functions because of their specific loca-
tions and microenvironment. By using a model of cultured
precision-cut liver slices, the behavior of the myofibro-
blast subpopulations during remodeling differs depend-
ing on the experimental model,141 the pathological
situation, and the disease cause.142 HSC-derived myofi-
broblasts can lose -SMA expression without undergoing
cell death, whereas in similar conditions, PF-derived
myofibroblasts die by apoptosis. HSC-derived myofibro-
blasts are involved in blood flow regulation and hepato-
cellular healing. The appearance of the myofibroblast
phenotype in HSCs may lead to disordered vascular re-
modeling after liver injury, inducing ischemia and then
fibrosis. PF-derived myofibroblasts are involved in scar-
ring.143
Remodeling of the Fibrotic Injury and Potential
Therapies
The traditional view of liver fibrosis as an irreversible
process is obsolete, and the development of liver fi-
brosis is thought to be a dynamic and potentially bidi-
rectional process. Because of the liver’s extraordinary
regeneration potential, myofibroblast and fibrosis re-
version strategies may be more applicable than in
other organs, such as the lung.130 Spontaneous reso-
lution of scarring is seen in animal models of liver
fibrosis and in human trials in which the stimuli respon-
sible for long-term or repeated hepatic damage are
successfully removed. Key players in the process are
myofibroblasts, matrix metalloproteinases, and matrix
metalloproteinase inhibitors. However, it is still unclear
whether advanced fibrotic or cirrhotic liver can revert
back to normal architecture after the removal of profi-
brotic factors. It is conceivable that there is a point of
no return, even for this highly regenerative organ. Im-
portant quantities of elastin and extensively cross-
linked ECM components seem to be features of irre-
versibility.144 Numerous preclinical studies145 aimed at
inhibiting myofibroblast activity and fibrosis progres-
sion in liver have been developed, but their translation
into the clinic remains limited.
Stromal Reaction to Epithelial Tumors
Cancer cells do not exist independently but interact dy-
namically with local and distant host cells, best concep-
tualized as a gradually evolving microenvironment oreven ecosystem.6 Nonredundant changes in a single
element may inevitably alter the organization of the whole
system and may drive tumor initiation, invasion, and me-
tastasis. Morphological evidence of host participation in
the primary tumor, the premetastatic niche, and meta-
static sites includes the following: i) desmoplasia con-
sisting of carcinoma-associated fibroblasts (CAFs)
and ECM; ii) inflammation and immune response repre-
sented by lymphocytes, macrophages, and dendritic
cells; and iii) angiogenesis evidenced by newly formed
blood vessels and lymph vessels. Herein, we focus on
the prominent role of CAFs as host cells in the tumor
microenvironment. Phenotypically, CAFs closely resem-
ble myofibroblasts exhibiting different levels of specific
marker expression. This raises the possibility that tumor-
associated myofibroblasts fall into a diversity of functional
subtypes, similar to what has been shown for inflamma-
tory cells and macrophages.122
Origins of Myofibroblasts and CAF in Tumor Stroma
Current understanding of the origin and molecular
events surrounding the genesis of myofibroblasts and
CAFs in tumor stroma is still a matter of debate. CAFs
are thought to arise from several mobilized cell types,
such as tissue-resident MSCs or fibroblasts, as well as
recruited bone marrow–derived MSCs and fibro-
cytes.122 Alternatively, or in addition, CAFs may origi-
nate from multiple resident precursors, such as en-
dothelial cells, myoepithelial cells, epithelial (cancer)
cells, smooth muscle cells, adipocytes, and stellate
cells. These findings suggest a high degree of plastic-
ity and/or a diversity of origins for tumor myofibro-
blasts. This diversity may also explain the heteroge-
neous phenotype of myofibroblast populations observed
within tumors.122
Specific Roles and Features of Myofibroblasts in the
Tumor Environment
Traditionally, biomarker research has focused on mo-
lecular characteristics of the cancer cells, but increasing
evidence suggests that myofibroblasts may refine the
prognostic assessment of tumors and may provide pre-
dictive information about response to chemotherapy.
Gene expression profiles of laser-capture microdis-
sected tumor-associated host cells from primary breast
tumors yield prognostic signatures strongly associated
with a poor disease-specific survival. A wound-response
signature, containing genes implicated in tissue remod-
eling, migration, angiogenesis, and inflammation, is es-
tablished from 50 fibroblast cultures whose expression
changed after exposure to 10% serum. Patients with
breast cancer whose tumors express this wound-re-
sponse signature have a markedly reduced overall sur-
vival and distant metastasis-free survival compared with
those with tumors that do not express this signature.80
Immunohistochemical analysis of breast tumors also re-
veals that many of the proteins encoded by genes iden-
tified in the previously mentioned signatures are ex-
pressed by myofibroblasts, indicating their striking
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rived growth factor receptor , LOXL2, caveolin-1, and
CD10 in CAFs has been correlated with poor clinical
outcome in multiple cancer types, such as breast, colon,
pancreas, and liver.69,146–148 Increased co-expression of
LOXL2 and -SMA in colon and breast cancer suggests
that myofibroblasts are the main producers of LOXL2.
The ECM, including cross-linked collagen type I, has an
influence on therapeutic response. Moreover, a tumor-
associated host cell gene expression signature present
in estrogen receptor–negative breast tumors predicts re-
sistance to neo-adjuvant chemotherapy with 5-fluoroura-
cil, epirubicin, and cyclophosphamide.149
In the primary tumor microenvironment, resident hu-
man mammary and prostate fibroblasts exhibit autocrine
signaling loops mediated by TGF1 and chemokines and
differentiated into myofibroblasts.150 Epigenetic regula-
tion by miRNAs and oxidative stress caused by reactive
oxygen species in the primary tumor promote myofibro-blast differentiation67 and secretion of senescence-asso-
ciated pro-inflammatory cytokines, such as IL-6 and IL-
8.151 When considering the tumor environment as an
ecosystem, however, it is important to note that a tumor is
not composed solely of cancer cells and myofibroblasts.
The secretion of pro-inflammatory cytokines by myofibro-
blasts may influence the recruitment of inflammatory
cells, which, in addition to their immunomodulatory activ-
ity, may also stimulate invasion of cancer cells. CAFs
isolated from the initial hyperplastic stage in multistep
skin tumorigenesis exhibit activated expression of the
pro-inflammatory cytokine IL-6.152 More important, chem-
ical and physical insults encountered during therapeutic
interventions may also cause stress-induced cellular se-
nescence and reciprocal activation of pro-inflammatory,
prosurvival, and pro-invasive pathways in the local eco-
system and at distant anatomical locations.153
Primary tumor–induced remodeling of distant ecosys-
tems, which initiates metastatic niche formation and host
Figure 2. Tumor myofibroblasts. A schematic
view highlights the cross signaling (double ar-
rows) within and between local and distant
tumor ecosystems. Arrows indicate displace-
ment of cells between ecosystems; dashed ar-
rows, conversion from one cell type into an-
other; positive arrows, stimulation; and bold
arrows, importance of the signaling.
Figure 3. The myofibroblast in the center of
attention. Anti-fibrotic therapies can be de-
signed to interfere with the extracellular chem-
ical and mechanical factors that lead to myofi-
broblast formation from a variety of different
precursors. Alternatively, one might interfere
with intracellular signaling pathways, transcrip-
tion regulators, and epigenetic mechanisms that
specifically modulate myofibroblast differentia-
tion. Other potential anti-fibrotic targets are spe-
cific features of the differentiated myofibroblast,
such as -SMA in the contractile apparatus, spe-
cific integrins, and ECM proteins. Other strate-
gies aim to induce myofibroblast regression
and/or apoptosis (modified and reproduced
with permission from the study by Hinz and
Gabbiani161).
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products released into the circulation (Figure 2). The
primary tumor signals to the bone marrow and stimulates
the release of MSCs into the circulation, with recruitment
by stromal cell–derived factor-1 chemokine gradients to
the tumor site, where they are converted into myofibro-
blasts by TGF1.154 Moreover, osteopontin released by
an aggressive xenograft mobilizes granulin-secreting
ScaIcKitCD45 bone marrow–derived hematopoietic
cells into the circulation.72 These granulin-secreting cells
home to a second otherwise quiescent or indolent tumor
in the same animal. Granulin accumulation converts res-
ident fibroblasts into myofibroblasts and stimulates pro-
gression of an otherwise indolent tumor.72 Secretory
products from the primary tumor ecosystem recruit MSCs
or hematopoietic cells from the bone marrow but also
may promote myofibroblast differentiation in distant loci.
Thus, TGF1, packaged in secreted nanovesicles
termed exosomes, converts fibroblasts into myofibro-
blasts at distant organs and may prepare metastatic
niches by focalized production of a fibronectin scaf-
fold.155,156 Alternatively, metastatic cancer cells can
bring their own soil, including myofibroblasts, from the
primary ecosystem to the distant ecosystem, as shown
for the lung. Comigrating myofibroblasts provide prosur-
vival signals in the circulation and an early growth advan-
tage in the ectopic lung site.157
Thus far, we have emphasized the invasion- and me-
tastasis-promoting effects of myofibroblasts. However,
transgenic mouse experiments suggest that suppressive
signals derived from resident tissue fibroblasts can also
control tumor initiation and progression.80 For example,
disruption of the TGF receptor type II (TGFBR2) gene in
fibroblasts results in invasive squamous cell carcinoma of
the forestomach.158 In a model of prostate cancer, loss of
p53 function in fibroblasts precedes inactivation of p53 in
the epithelium.159 Targeted genetic inactivation of the
phosphatase and tensin homologue (PTEN), a tumor sup-
pressor with lipid and protein phosphatase activity, in
fibroblasts of mouse mammary glands accelerates the
initiation and progression of ErbB2-driven mammary ep-
ithelial tumors characterized by massive accumulation of
collagen type I and infiltration of F4/80-positive macro-
phages.160 In conclusion, the complex molecular mech-
anisms that govern cancer cell–myofibroblast interac-
tions in the primary tumor and in distant ecosystems
justify the need for systems-level approaches to advance
the field.
Conclusion and Perspectives
Based on the biological observations pinpointing the
mechanisms of differentiation and activity of the myofi-
broblast, many attempts have been made to target them
in anti-fibrotic therapies (Figure 3). However, no clinically
effective compound has yet been identified, although
several possibilities continue to be under investigation.
Emerging and promising, but not yet clinically tested,
strategies to counteract fibrosis include the use of
miRNAs as potential therapeutic targets.43 Another strat-egy is to interfere with collagen cross-linking and ECM
stiffening by controlling the activities of LOX,68 LOXL2,70
and specific lysyl hydroxylases.162
The capacity of cytokines to inhibit -SMA expression
by fibroblastic cells suggests a different strategy. In the
case of interferon-, locally applied cytokine is found to
be effective for treatment of Dupuytren’s nodules in one
study,60 but this result needs confirmation. Another more
recent example for anti-fibrotic cytokines is CXCL10,
which effectively treated lung fibrosis in an animal
model.61 The complementary approach is to block profi-
brotic cytokines, among which TGF1 is the most attrac-
tive target. However, administration of TGF1-inhibiting
drugs and antibodies has shown little success in animal
and human studies, indicating that targeting a single
cytokine is unlikely to be successful.52 More promising
strategies appear to target TGF1 profibrotic cofactors,
such as CCN274 or the ECM protein extradomain A fi-
bronectin.75,76 Alternatively, TGF1 can be counteracted
at the level of its activation from latent stores; possible
targets in the activation process are fibroblast/myofibro-
blast-associated integrins v3, v5, and 81 integ-
rin50 and the epithelial integrin v6.163 It is conceivable
that inhibiting these integrins has alternative suppressing
effects on myofibroblast development. Other integrins
that have contributed to fibrosis and myofibroblast differ-
entiation through different pathways include 31,
111, and v3, and all represent possible therapeutic
targets.11
Other interesting approaches are based on the possi-
bility of terminating myofibroblast persistence by induc-
ing their apoptosis164 or their reversion to nonfibrogenic
cell phenotypes.108 In the case of the former, the ability of
nitric oxide to induce myofibroblast apoptosis165 sug-
gests a possible therapeutic approach, such as by the
use of phosphodiesterase-5 inhibitors.166 Finally, the ex-
perimental observation that the acetylated N-terminal
peptide of -SMA, Ac-EEED, inhibits both -SMA and
collagen type I expression, on intracellular delivery into
myofibroblasts, makes this peptide a potential suppres-
sor of fibrotic changes. This possibility has been suc-
cessfully tested on experimental wound healing.167 We
believe that these different approaches will eventually
open new therapeutic avenues.
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